Scientific article
English

Rapamycin in islet transplantation: friend or foe?

Published in

Transplant international, vol. 22, no. 2, p. 153-161

Publication date

2009

Abstract

The Edmonton protocol was undoubtedly a major step forward in the history of islet transplantation. Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols. As time reveals the somewhat disappointing long-term results achieved with the Edmonton protocol, a number of publications have appeared addressing the potential beneficial or deleterious role of rapamycin on islet cell engraftment, function survival and regeneration, as well as on its side-effects in human subjects. This paper reviews the sometimes contradictory evidence on the impact of rapamycin in islet transplantation.

Keywords

  • Diabetes Mellitus/drug therapy/immunology
  • Humans
  • Immune Tolerance/drug effects
  • Immunosuppressive Agents/adverse effects/pharmacology
  • Insulin-Secreting Cells/drug effects
  • Islets of Langerhans Transplantation/immunology
  • Sirolimus/adverse effects/pharmacology

Citation (ISO format)

BERNEY, Thierry, SECCHI, Antonio. Rapamycin in islet transplantation: friend or foe? In: Transplant international, 2009, vol. 22, n° 2, p. 153–161. doi: 10.1111/j.1432-2277.2008.00743.x

Main files (1)

Article (Accepted version)

Identifiers

Journal ISSN

0934-0874
652views
0downloads

Technical informations

Creation

20/03/2009 09:39:00

First validation

20/03/2009 09:39:00

Update

14/03/2023 15:03:34

Status update

14/03/2023 15:03:34

Last indexation

29/10/2024 11:23:15
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated